Opus Genetics, a clinical-stage biopharmaceutical company, has secured $25.0 million in new investment capital. This funding round provides significant resources as the company continues to advance its therapeutic pipeline focused on ophthalmic disorders, particularly inherited retinal diseases.
The company specializes in developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other eye conditions. Opus Genetics' pipeline includes AAV-based gene therapies targeting IRDs such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa, conditions that often lead to severe vision impairment or blindness. Its lead gene therapy candidates are OPGx-LCA5, currently in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy designed to address BEST1-related retinal degeneration. Additionally, Opus Genetics is advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy already approved for one indication and undergoing two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances.
This substantial capital infusion is intended to support the continued development of Opus Genetics' clinical programs and to expand its research and development initiatives. The investment underscores confidence in the company's scientific approach and its potential to address significant unmet medical needs within ophthalmology through both gene therapy and small molecule platforms.
With this funding, Opus Genetics is positioned to accelerate its efforts in bringing innovative treatments to patients suffering from debilitating eye conditions. The company remains committed to progressing its pipeline and ultimately delivering therapies that can improve vision and quality of life for individuals affected by inherited retinal diseases and other ophthalmic disorders, aiming to make a meaningful impact on patient care.
.png&w=3840&q=75)
